Clare Khan

Clare Khan

Director/Board Member at SOLID BIOSCIENCES INC.

Net worth: - $ as of 2024-04-29

72 year
Health Technology
Consumer Services

Profile

Clare Khan is currently serving as an Independent Director at Solid Biosciences, Inc. since 2021.
Additionally, Dr. Khan holds the position of Strategy Officer-Research & Development at X-Vax Technology, Inc. since 2018.
Prior to these current roles, Dr. Khan was the President of Clare Kahn Pharma Consulting LLC starting from 2016.
Dr. Khan's former positions include Vice President-Global Innovative Pharma at Pfizer Inc. from 2014 to 2016 and Vice President-Regulatory Affairs at GSK Plc from 1999 to 2010.
Dr. Khan also worked as an Assistant Professor at the University of Pennsylvania from 1981 to 1985.
Dr. Khan obtained a doctorate degree from the Royal Postgraduate Medical School in 1981.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-03-30 0 ( -.--% ) - $ 2024-04-29

Clare Khan active positions

CompaniesPositionStart
SOLID BIOSCIENCES INC. Director/Board Member 2021-03-01
Chief Tech/Sci/R&D Officer 2019-09-30
Clare Kahn Pharma Consulting LLC President 2016-05-31
All active positions of Clare Khan

Former positions of Clare Khan

CompaniesPositionEnd
PFIZER, INC. Corporate Officer/Principal 2016-05-31
GSK PLC General Counsel 2009-12-31
University of Pennsylvania Corporate Officer/Principal 1984-12-31
See the detail of Clare Khan's experience

Training of Clare Khan

Royal Postgraduate Medical School Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Clare Khan's experience

Connections

100 +

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies3
PFIZER, INC.

Health Technology

GSK PLC

Health Technology

SOLID BIOSCIENCES INC.

Health Technology

Private companies2

Health Technology

Clare Kahn Pharma Consulting LLC

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW